Mechanisms of Resistance in CML and the Emerging Role of Asciminib and Other Next-Generation Inhibitors
نویسندگان
1 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
2 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
3 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
4 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
doi
چکیده
Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL1 fusion gene that confers constitutive tyrosine kinase activity. Although tyrosine kinase inhibitors (TKIs) have revolutionized CML therapy, resistance remains a major clinical challenge, primarily due to kinase domain mutations, leukemic stem cell persistence, and compensatory signalling pathways. Asciminib, a novel allosteric ...
